Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | STAMBP | O95630 | 1/20 | 0.41 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173756 | 0.86 | MGAM (0.57) | PSMD14MGAMHDAC6SMN1; SMN2EGLN1 | |
| SCHEMBL20173757 | 0.82 | ALOX15 (0.50) | HPGDSPSMD14HDAC6HDAC3HDAC1 | |
| SCHEMBL5405254 | 0.82 | HPGDS (0.55) | HPGDSTNIKPSMD14STAMBPCOPS5 | |
| SCHEMBL15125086 | 0.80 | HPGDS (0.54) | HPGDSPSMD14STAMBPCOPS5CHEK2 | |
| SCHEMBL10199417 | 0.78 | NPC1 (0.44) | NPC1SCN4ARAB9ASMN1; SMN2EGLN1 | |
| SCHEMBL27471536 | 0.76 | HPGDS (0.50) | HPGDSTNIKPSMD14STAMBPCOPS5 | |
| SCHEMBL3868878 | 0.76 | HPGDS (0.50) | HPGDSTNIKPSMD14STAMBPCOPS5 | |
| SCHEMBL15775057 | 0.76 | ALPL (0.50) | HPGDSPSMD14STAMBPCOPS5CHEK2 | |
| SCHEMBL3845152 | 0.76 | HPGDS (0.78) | HPGDS | |
| SCHEMBL22280319 | 0.76 | TGFBR1 (0.49) | NPC1SCN4ARAB9ASMN1; SMN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | HPGDS 1294/4885TNIK 3982/4885PSMD14 3043/4885 |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK3 | HPGDS 3675/4885TNIK 31/4885PSMD14 1285/4885 |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | IRAK4, IRAK1, IRAK3 | HPGDS 3675/4885TNIK 31/4885PSMD14 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.